Woodline Partners’s Celldex Therapeutics CLDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $30.5M | Buy |
1,500,455
+312,026
| +26% | +$6.35M | 0.16% | 189 |
|
|
2025
Q1 | $21.6M | Sell |
1,188,429
-825,586
| -41% | -$15M | 0.14% | 216 |
|
|
2024
Q4 | $50.9M | Sell |
2,014,015
-327,106
| -14% | -$8.27M | 0.34% | 78 |
|
|
2024
Q3 | $79.6M | Buy |
2,341,121
+1,583,350
| +209% | +$53.8M | 0.67% | 24 |
|
|
2024
Q2 | $28M | Buy |
757,771
+6,711
| +0.9% | +$248K | 0.27% | 116 |
|
|
2024
Q1 | $31.5M | Buy |
751,060
+363,408
| +94% | +$15.3M | 0.29% | 104 |
|
|
2023
Q4 | $15.4M | Buy |
387,652
+280,156
| +261% | +$11.1M | 0.17% | 180 |
|
|
2023
Q3 | $2.96M | Buy |
107,496
+52,997
| +97% | +$1.46M | 0.03% | 364 |
|
|
2023
Q2 | $1.85M | Sell |
54,499
-972
| -2% | -$33K | 0.02% | 437 |
|
|
2023
Q1 | $2M | Buy |
+55,471
| New | +$2M | 0.03% | 424 |
|
|
2022
Q3 | – | Sell |
-64,454
| Closed | -$1.74M | – | 763 |
|
|
2022
Q2 | $1.74M | Sell |
64,454
-514,738
| -89% | -$13.9M | 0.03% | 451 |
|
|
2022
Q1 | $19.7M | Buy |
579,192
+319,297
| +123% | +$10.9M | 0.32% | 91 |
|
|
2021
Q4 | $10M | Buy |
+259,895
| New | +$10M | 0.14% | 193 |
|